Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSRA-196 first-in-human phase 1/2 study in adults with PiZZ alpha-1 antitrypsin deficiency with lung and/or liver disease
2025-523497-16-00Phase 2Authorised
- Sponsor
- Tessera Therapeutics
- Start
- Oct 2026
- Modality
- Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 6
01
Overview
Phase 2, open-label trial of TSRA-196 in alpha-1 antitrypsin deficiency (AATD) and alpha-1 antitrypsin deficiency emphysema (5 arms), sponsored by Tessera Therapeutics. Planned start Oct 2026; status: authorised.
02
Drugs
TSRA-196
03
Conditions
alpha-1 antitrypsin deficiency (AATD)alpha-1 antitrypsin deficiency emphysema
Beyond the preview
Go deeper on 2025-523497-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523497-16-00.